Cervical cancer screening has duplex screening including HPV test, i.e. human papillomavirus test, and cytology test, i.e. TCT test. HPV screening methods include: 1. nucleic acid in situ hybridization, which can detect HPV typing and DNA with high sensitivity, but the operation is complicated and not easy to promote; 2. spot blotting, which has lower sensitivity and specificity than nucleic acid in situ hybridization, and there may be radioactive contamination during the test, but it is economical. But economically applicable; 3, in situ hybridization, i.e., detection by non-radioactive probes, with low false-positive rate and low sensitivity; 4, hybridization capture, i.e., HC-2 detection, which can mainly detect type 15 high-risk HPV and cannot be typed for HPV. duplex screening by HPV examination and cytology can make up for the deficiency of cytology single screening. Gynecologic HPV testing is an important cervical cancer screening tool.